CD58 Antigens

DBCAT004969Pharmacologic class

Glycoproteins with a wide distribution on hematopoietic and non-hematopoietic cells and strongly expressed on MACROPHAGES. CD58 mediates cell adhesion by binding to CD2; (CD2 ANTIGENS); and this enhances antigen-specific T-cell activation. A DrugBank category of 1 drug. 1 of them is approved.

Drugs: Alefacept

What you can answer from here — as of July 18, 2019

1DrugEach linked to its full drug card

Listed above

4Drug targetsEvery drug–target pair in the class, with bond type

2Marketed productsAcross the regions we cover, with dosage forms and routes

1Route of administrationHow the drugs in this class are given

Which targets do CD58 Antigens share, and which companies have late-stage candidates in this class?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account